title: Genome-wide histone acetylation is altered in a transgenic mouse model of Huntington's disease.
abstract: In Huntington's disease (HD; MIM ID #143100), a fatal neurodegenerative disorder, transcriptional dysregulation is a key pathogenic feature. Histone modifications are altered in multiple cellular and animal models of HD suggesting a potential mechanism for the observed changes in transcriptional levels. In particular, previous work has suggested an important link between decreased histone acetylation, particularly acetylated histone H3 (AcH3; H3K9K14ac), and downregulated gene expression. However, the question remains whether changes in histone modifications correlate with transcriptional abnormalities across the entire transcriptome. Using chromatin immunoprecipitation paired with microarray hybridization (ChIP-chip), we interrogated AcH3-gene interactions genome-wide in striata of 12-week old wild-type (WT) and transgenic (TG) R6/2 mice, an HD mouse model, and correlated these interactions with gene expression levels. At the level of the individual gene, we found decreases in the number of sites occupied by AcH3 in the TG striatum. In addition, the total number of genes bound by AcH3 was decreased. Surprisingly, the loss of AcH3 binding sites occurred within the coding regions of the genes rather than at the promoter region. We also found that the presence of AcH3 at any location within a gene strongly correlated with the presence of its transcript in both WT and TG striatum. In the TG striatum, treatment with histone deacetylase (HDAC) inhibitors increased global AcH3 levels with concomitant increases in transcript levels; however, AcH3 binding at select gene loci increased only slightly. This study demonstrates that histone H3 acetylation at lysine residues 9 and 14 and active gene expression are intimately tied in the rodent brain, and that this fundamental relationship remains unchanged in an HD mouse model despite genome-wide decreases in histone H3 acetylation.
authors: Department of Neurology, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Charlestown, Massachusetts, United States of America.
authors: Karen N
authors: KN
authors: McFarland
authors: Sudeshna
authors: S
authors: Das
authors: Ting Ting
authors: TT
authors: Sun
authors: Dmitri
authors: D
authors: Leyfer
authors: Eva
authors: E
authors: Xia
authors: Gavin R
authors: GR
authors: Sangrey
authors: Alexandre
authors: A
authors: Kuhn
authors: Ruth
authors: R
authors: Luthi-Carter
authors: Timothy W
authors: TW
authors: Clark
authors: Ghazaleh
authors: G
authors: Sadri-Vakili
authors: Jang-Ho J
authors: JH
authors: Cha
mesh_terms: D000107:Acetylation / Q000187:drug effects; D000818:Animals; D003342:Corpus Striatum / Q000378:metabolism* / Q000473:pathology; D004195:Disease Models, Animal; D015536:Down-Regulation / Q000187:drug effects / Q000235:genetics*; D056426:Genetic Loci; D016678:Genome; D055106:Genome-Wide Association Study; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology; D006657:Histones / Q000235:genetics / Q000378:metabolism*; D006816:Huntington Disease; D008297:Male; D051379:Mice; D008822:Mice, Transgenic
chemical_list: D056572:Histone Deacetylase Inhibitors; D006657:Histones